ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 332.30K | 346.30K | 345.80K | 351.00K | 332.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 332.30K | 346.30K | 345.80K | 351.00K | 332.30K |
| Cost of Revenue | 1.07M | 1.03M | 1.03M | 1.03M | 1.75M |
| Gross Profit | -734.20K | -679.20K | -682.30K | -681.10K | -1.42M |
| SG&A Expenses | 5.98M | 6.09M | 6.70M | 6.82M | 8.43M |
| Depreciation & Amortization | 2.06M | 2.07M | 2.11M | 2.16M | 2.19M |
| Other Operating Expenses | 280.50K | 302.50K | 387.80K | 356.00K | 279.80K |
| Total Operating Expenses | 10.86M | 11.36M | 11.89M | 11.86M | 14.22M |
| Operating Income | -10.52M | -11.01M | -11.54M | -11.51M | -13.89M |
| Income Before Tax | -25.57M | -25.82M | -26.16M | -25.89M | -31.16M |
| Income Tax Expenses | -1.46M | -1.47M | -1.48M | -1.49M | -4.29M |
| Earnings from Continuing Operations | -24.12 | -24.36 | -24.68 | -24.39 | -26.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.12M | -24.36M | -24.68M | -24.39M | -26.86M |
| EBIT | -10.52M | -11.01M | -11.54M | -11.51M | -13.89M |
| EBITDA | -8.79M | -9.27M | -9.76M | -9.68M | -12.00M |
| EPS Basic | -0.32 | -0.33 | -0.34 | -0.33 | -0.38 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.11 | -0.11 | -0.14 |
| EPS Diluted | -0.33 | -0.33 | -0.34 | -0.34 | -0.39 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.11 | -0.11 | -0.14 |
| Average Basic Shares Outstanding | 302.28M | 296.53M | 291.76M | 288.25M | 283.92M |
| Average Diluted Shares Outstanding | 302.28M | 296.53M | 291.76M | 288.25M | 283.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |